In the latest trading session, 0.83 million Gossamer Bio Inc (NASDAQ:GOSS) shares changed hands as the company’s beta touched 1.86. With the company’s most recent per share price at $1.35 changed hands at -$0.05 or -3.57% at last look, the market valuation stands at $305.92M. GOSS’s current price is a discount, trading about -18.52% off its 52-week high of $1.60. The share price had its 52-week low at $0.50, which suggests the last value was 62.96% up since then.
Analysts gave the Gossamer Bio Inc (GOSS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.25. If we narrow down to specifics, the data shows that 0 out of 10 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 3 recommended GOSS as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. Gossamer Bio Inc’s EPS for the current quarter is expected to be -0.17.
Gossamer Bio Inc (NASDAQ:GOSS) trade information
Instantly GOSS was in red as seen in intraday trades today. With action 3.05%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 49.24%, with the 5-day performance at 3.05% in the green. However, in the 30-day time frame, Gossamer Bio Inc (NASDAQ:GOSS) is 52.39% up.
The consensus price target for the stock as assigned by Wall Street analysts is 4, meaning bulls need an upside of 66.25% from its recent market value. According to analyst projections, GOSS’s forecast low is 2 with 5 as the target high. To hit the forecast high, the stock’s price needs a -270.37% plunge from its current level, while the stock would need to soar -48.15% for it to hit the projected low.
Gossamer Bio Inc (GOSS) estimates and forecasts
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 7.02M. 6 analysts are of the opinion that Gossamer Bio Inc’s revenue for the current quarter will be 3.48M. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 11.99%. The 2025 estimates are for Gossamer Bio Inc earnings to increase by 76.06%, but the outlook for the next 5-year period is at 26.42% per year.
Gossamer Bio Inc (NASDAQ:GOSS)’s Major holders
ARTAL GROUP S.A. holds the second largest percentage of outstanding shares, with 5.8832% or 13.31 million shares worth $11.99 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Fidelity Select Portfolios – Biotechnology and Vanguard Total Stock Market Index Fund. With 7.91 shares estimated at $10.91 million under it, the former controlled 3.49% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 3.46% of the shares, roughly 7.84 shares worth around $10.81 million.
